Engineered trivalent immunogen adjuvanted with a STING agonist confers protection against Trypanosoma cruzi infection
Chagas disease: protecting from chronic parasitic disease An amalgamation of parasitic proteins may be the first effective vaccine against the as yet untreatable chronic phase of Chagas disease. The infliction, caused by the parasite Trypanosoma cruzi (T. cruzi), is the world’s leading cause of infe...
Main Authors: | Andrés Sanchez Alberti, Augusto E. Bivona, Natacha Cerny, Kai Schulze, Sebastian Weißmann, Thomas Ebensen, Celina Morales, Angel M. Padilla, Silvia I. Cazorla, Rick L. Tarleton, Carlos A. Guzmán, Emilio L. Malchiodi |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2017-04-01
|
Series: | npj Vaccines |
Online Access: | https://doi.org/10.1038/s41541-017-0010-z |
Similar Items
-
Trypanosoma cruzi 80 kDa prolyl oligopeptidase (Tc80) as a novel immunogen for Chagas disease vaccine.
by: Augusto E Bivona, et al.
Published: (2018-03-01) -
Activity of Estafietin and Analogues on <i>Trypanosoma cruzi</i> and <i>Leishmania braziliensis</i>
by: Valeria P. Sülsen, et al.
Published: (2019-03-01) -
In Vitro, In Vivo, and In Silico Studies of Cumanin Diacetate as a Potential Drug against Trypanosoma cruzi Infection
by: Andrés Sánchez Alberti, et al.
Published: (2021-12-01) -
Assessment of sesquiterpene lactones isolated from Mikania plants species for their potential efficacy against Trypanosoma cruzi and Leishmania sp.
by: Laura C Laurella, et al.
Published: (2017-09-01) -
Oxonitrogenated Derivatives of Eremophilans and Eudesmans: Antiproliferative and Anti-<i>Trypanosoma cruzi</i> Activity
by: María F. Beer, et al.
Published: (2022-05-01)